Appropriateness of treatment options in patients with metastatic castrationresistant prostate cancer with a focus on radium-223: outcomes of a Belgian multidisciplinary Consensus Meeting

BJMO - volume 13, issue 6, october 2019

P. Ost MD, PhD, D. Schrijvers MD, PhD, L. Duck MD, PhD, M. Gizzi MD, K. Goffin MD, PhD, S. Joniau MD, PhD, S. Rottey MD, PhD, T. Roumeguère MD, E. Seront MD, PhD, N. Withofs MD, PhD, B. Tombal MD, PhD


The treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) has changed dramatically with the approval of a variety of therapeutic agents including abiraterone acetate, cabazitaxel, docetaxel, enzalutamide and radium-223 dichloride and the introduction of docetaxel and abiraterone acetate in combination with androgen deprivation therapy in newly diagnosed metastatic prostate cancer. Evidence on the optimal sequence of these therapies is scarce. In practice, the most appropriate treatment (sequence) depends on patient and disease characteristics. This article summarises the recommendations of a multidisciplinary group of Belgian experts in sequencing treatments for patients with mCRPC, with a focus on radium-223 dichloride.

(BELG J MED ONCOL 2019;13(6): 240–250)

Read more

Current immunotherapeutic approach to bladder cancer

BJMO - 12, issue 3, february 2018

E. Seront MD, PhD


Multiple immune checkpoint inhibitors (ICIs) are currently available for the treatment of bladder cancer. The question raised by Dr Seront in his lecture was: “which agent should be used for which patient?”

Read more

Immunotherapy for genitourinary cancers: where are we?

BJMO - volume 11, issue 9, february 2017

E. Seront MD, PhD, J.P. Machiels MD, PhD

Immunotherapy harnesses the immune system to recognize and destroy cancer cells. This review focuses on the different agents that are currently approved in genitourinary cancers and highlights promising therapeutic strategies in this field. The clinical data generated in advanced urological cancer, advanced renal cell carcinoma (RCC) and metastatic prostate cancer will be discussed

Read more

3rd Belgian Multidisciplinary Meeting on Urological Cancers

BJMO - volume 10, issue 6, september 2016

T. Vermassen PhD, R. de Wit MD, PhD, R. van Velthoven MD, PhD, S. Albisinni MD, N. Martinez Chanza MD, F. Aoun MD, MSc, E. Seront MD, PhD, S. Rottey MD, PhD


Due to the success of last year, a third national Belgian Multidisciplinary scientific meeting on Urological Cancers was held with the cooperation of medical oncologists (BSMO), urologists (BAU) and radiation oncologists (ABRO/BVRO). It was a great opportunity to build bridges between these three important specialisms involved in the treatment of urological cancers.
The steering committee of the meeting consisted of J.P. Machiels, G. Pelgrims, S. Rottey (members of BSMO), L. Hoekx, S. Joniau, T. Roumeguere (members of BAU), O. De Hertogh, G. De Meerleer and Y. Neybuch (members of ABRO-BVRO). The third meeting, held in La Hulpe, Brussels on March 5th, 2016 was a great success with more than 100 attendees of the different specialisms involved.
In this report of the meeting you can find a summary of the most important lectures given at the symposium.

(BELG J MED ONCOL 2016;10(6):232–235)

Read more